Hepatitis C News

The Canadian Task Force on Preventive Health Care recommends against screening for hepatitis C virus in low-risk patients, including baby boomers.

AMSTERDAM — Nearly 100% of a cohort of non-cirrhotic patients with HCV who had undergone liver transplantation responded to treatment with glecaprevir/pibrentasvir, according to data presented at the International Liver Congress.

AMSTERDAM — Adherence to treatment and subsequent sustained virologic response were unaffected by drug use in a study of patients enrolled in an opioid agonist treatment program, according to a presenter at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, Andrew Talal, MD, MPH, from the University of Buffalo, New York, discusses alternative paths to ensure patients with substance use disorders with hepatitis C can receive appropriate care.

AMSTERDAM — Six weeks of triple combination therapy induced sustained virologic response in a cohort of patients with genotype 1 HCV but not genotype 3, according to data presented at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, Andrew Talal, MD, MPH, from the University of Buffalo, New York, discusses results of a study that used fine-needle aspiration to determine HCV RNA decline in plasma in patients treated with a direct-acting antiviral regimen.

AMSTERDAM — A fixed, half-dose combination of Harvoni was associated with sustained virologic response rates of 99% or greater in a cohort of children aged 6 to 11 years, according to data presented at the International Liver Congress.

AMSTERDAM — A presenter at today’s viral hepatitis session at the International Liver Congress called on the clinical community to push the envelope in using generic direct-acting antiviral therapies.

AMSTERDAM — Approximately one-third of children under 18 years in the United Kingdom with hepatitis C developed serious long-term liver disease, according to data presented at the International Liver Congress.

AMSTERDAM — Zepatier was associated with SVR12 rates above 95% in a real-world, Veterans Affairs cohort, according to data presented at the International Liver Congress.